Integrated Diagnostics Holdings PLC Notice of Extraordinary General Meeting (5264H)
04 Dicembre 2020 - 8:00AM
UK Regulatory
TIDMIDHC
RNS Number : 5264H
Integrated Diagnostics Holdings PLC
04 December 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF
SUCH JURISDICTION.
Publication of Circular and Notice of Extraordinary General
Meeting
4 December 2020
On 17 November 2020, Integrated Diagnostics Holdings plc ("IDH"
or the "Company") announced that it was contemplating a possible
dual listing of its ordinary shares on the Egyptian Exchange (the
"EGX"), in relation to which it was examining possible transaction
structures.
Further to that announcement, the Company announces that it now
intends to proceed with the proposed dual listing on the EGX and
has today published a circular outlining the details of the dual
listing (the "Circular"), the necessary shareholder resolutions to
be considered at an Extraordinary General Meeting (the "EGM") and
the Notice of EGM.
The EGM will be held on Wednesday, 23 December 2020 at 1.00 pm
(GMT) / 3.00 pm local time (EET) at the Headquarters of IDH,
Building B216-F7, Smart Village, Giza, Egypt.
Due to the ongoing restrictions and safety concerns as a result
of the COVID-19 pandemic, the EGM will be run as a closed meeting
with shareholders unable to attend the meeting in person.
Shareholders are therefore strongly encouraged to submit their
proxy votes online via www.signalshares.com or CREST where
applicable. Votes must be received by 1.00 pm (GMT) / 3.00 pm local
time (EET) on Monday, 21 December 2020. It will not be possible for
shareholders to vote during the meeting.
The Board remains keen to encourage engagement with
shareholders. To that end, the directors would like to invite
questions from shareholders in advance of and during the EGM.
Should shareholders wish to submit questions to the Board prior to
the deadline for proxy voting they can do so, and these will be
responded to on an individual basis. In addition, the Board will
offer shareholders the opportunity to dial into the EGM, at which
time they can also submit questions to the Board.
Shareholders wishing to access the dial-in facility or submit
questions are asked to email
nancy.fahmy@idhcorp.com by close of business on Wednesday, 16 December 2020.
A copy of the Circular will shortly be available on the
Company's website: www.idhcorp.com and for inspection at the
National Storage Mechanism:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar
in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar
Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation,
as well as internationally recognised accreditations for its
portfolio of over 1,400 diagnostics tests. From its base of 462
branches as of 30 June 2020, IDH will continue to add laboratories
through a Hub, Spoke and Spike business model that provides a
scalable platform for efficient expansion. Beyond organic growth,
the Group's expansion plans include acquisitions in new Middle
Eastern and African markets where its model is well-suited to
capitalise on similar healthcare and consumer trends and capture a
significant share of fragmented markets. IDH has been a
Jersey-registered entity with a Standard Listing on the Main Market
of the London Stock Exchange (ticker: IDHC) since May 2015. Learn
more at idhcorp.com .
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOGEANADELEEFFA
(END) Dow Jones Newswires
December 04, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Integrated Diagnostics (LSE:IDHC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Integrated Diagnostics (LSE:IDHC)
Storico
Da Apr 2023 a Apr 2024